Bispecific Checkpoint Inhibitor Improves Survival in Advanced Gastric/GEJ Cancer

Source link :

SAN DIEGO — A bispecific immune checkpoint inhibitor significantly improved survival in advanced gastric/gastroesophageal junction (GEJ) cancer, irrespective of PD-L1 expression status, a large study from China showed. Median overall survival (OS) increased from 10.8 months with chemotherapy to 15.0 months with the addition of cadonilimab, which targets both PD-1 and CTLA-4. Results significantly favored […]

Author : News Health

Publish date : 2024-04-10 21:18:39

Copyright for syndicated content belongs to the linked Source.